Alkermes Plc (ALKS)vsHaleon plc (HLN)
ALKS
Alkermes Plc
$45.97
-0.30%
HEALTHCARE · Cap: $7.63B
HLN
Haleon plc
$9.19
-0.33%
HEALTHCARE · Cap: $44.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 569% more annual revenue ($11.15B vs $1.67B). HLN leads profitability with a 14.5% profit margin vs 4.0%. ALKS appears more attractively valued with a PEG of 1.96. HLN earns a higher WallStSmart Score of 51/100 (C-).
ALKS
Hold46
out of 100
Grade: D+
HLN
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+54.4%
Fair Value
$76.49
Current Price
$45.97
$30.52 discount
Intrinsic value data unavailable for HLN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 27.0% year-over-year
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Areas to Watch
Expensive relative to growth rate
4.0% margin — thin
Premium valuation, high expectations priced in
Earnings declined 99.4%
Expensive relative to growth rate
2.2% revenue growth
Grey zone — moderate risk
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALKS
The strongest argument for ALKS centers on Revenue Growth. Revenue growth of 27.0% demonstrates continued momentum.
Bull Case : HLN
The strongest argument for HLN centers on Price/Book, Operating Margin.
Bear Case : ALKS
The primary concerns for ALKS are PEG Ratio, Profit Margin, P/E Ratio. A P/E of 119.7x leaves little room for execution misses. Thin 4.0% margins leave little buffer for downturns.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Key Dynamics to Monitor
ALKS profiles as a growth stock while HLN is a value play — different risk/reward profiles.
ALKS carries more volatility with a beta of 0.26 — expect wider price swings.
ALKS is growing revenue faster at 27.0% — sustainability is the question.
HLN generates stronger free cash flow (792M), providing more financial flexibility.
Bottom Line
HLN scores higher overall (51/100 vs 46/100). ALKS offers better value entry with a 54.4% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alkermes Plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in the United States, Ireland and internationally. The company is headquartered in Dublin, Ireland.
Visit Website →Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?